SIGHT — Gensight Biologics SA Share News
0.000.00%
Last trade - 00:00- €17.21m
- €28.38m
- €0.00m
Brief: Gensight Biologics Announces Publication Of Results From LUMEVOQ RESCUE Pivotal Phase III Trial
Brief: Gensight Biologics Announces Partial Conversion Of Bonds
Brief: GenSight Biologics Announces Publication of Results from LUMEVOQ REVERSE Pivotal Phase III Trial
Brief: Gensight Biologics Announces Validation Of LUMEVOQ® Marketing Authorisation Application By EMA
Brief: Gensight Biologics Raises EUR 25 Mln In Oversubscribed Private Placement
Brief: Gensight Biologics Launches Capital Increase Of Around EUR 25 Mln
Brief: Gensight Biologics End-September Cash And Cash Equivalents Up At 18.1 Million Euros
Brief: GenSight Biologics Submits EU Marketing Authorisation Application For LUMEVOQ Gene Therapy
Brief: Gensight Biologics Draws Down Second Tranche Of Bonds From Kreos Capital
Brief: Gensight Biologics H1 Net Loss Narrows To EUR 14.1 Mln
Brief: Gensight Biologics To Submit LUMEVOQ For European Authorization In September
Brief: Gensight Biologics Obtains EUR 6.75 Mln State-Guaranteed Loan
Brief: Gensight To Submit Lumevoq For Marketing Authorisation in EU
Brief: Gensight Biologics Says It Is Financed Until End Of 2020
Brief: Gensight Biologics To Submit LUMEVOQ For European Approval In September 2020
Brief: Gensight Biologics Announces Positive Data For PIONEER Phase I/II Trial Of GS030
Brief: GenSight Biologics Updates On Operations In Context Of COVID-19
Brief: GenSight Biologics To Present GS010 (LUMEVOQ) Phase III Trials
Brief: Gensight Biologics End-Dec Cash And Cash Equivalents At 19.2 Million Euros